TUPRO-Melanoma is the first project of the Tumour Profiler (TUPRO) research collaboration, which in the long-term aims to generate data that will help to understand and report the individual tumour biology and the clinical parameters for patients with advanced malignancies using innovative molecular technologies and computational analyses for in-depth molecular profiling. TUPRO-Melanoma is an exploratory project that aims to establish a comprehensive platform for in-depth tumour profiling in patients suffering from advanced melanoma. Aims of this platform are to establish logistics and algorithms for integrative analyses and discover new molecular biomarker profiles/patterns.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Sample Processing and Report Generation (Tumor Biopsy, peripheral blood sample and stool sample)
Timeframe: through study completion, an average of 1 year
Classification of proposed treatment options (according to the one of the 7 categories below)
Timeframe: through study completion, an average of 1 year
Classification of Tumour Board's recommendations according to ESCAT (categories below)
Timeframe: through study completion, an average of 1 year
Time to first subsequent treatment (TTFST)
Timeframe: through study completion, at least 6 month of follow up
Time to first subsequent treatment (TTFST) ratio
Timeframe: through study completion, at least 6 month of follow up
Toxicity
Timeframe: through study completion, at least 6 month of follow up
Survival
Timeframe: through study completion, at least 6 month of follow up
Event free survival
Timeframe: through study completion, at least 6 month of follow up
Radiological tumour response
Timeframe: through study completion, at least 6 month of follow up